TY - JOUR
T1 - N-glycosylation of monoclonal light chains on routine MASS-FIX testing is a risk factor for MGUS progression
AU - Dispenzieri, Angela
AU - Larson, D. R.
AU - Rajkumar, S. V.
AU - Kyle, R. A.
AU - Kumar, S. K.
AU - Kourelis, Taxiarchis
AU - Arendt, Bonnie
AU - Willrcih, Maria
AU - Dasari, Surendra
AU - Murray, David
N1 - Funding Information:
Acknowledgements This research was supported by Mayo Clinic, Rochester, MN, US NIH CA186781, The Predolin Foundation, The JABBS Foundation.
Publisher Copyright:
© 2020, The Author(s), under exclusive licence to Springer Nature Limited.
PY - 2020/10/1
Y1 - 2020/10/1
N2 - Our group previously demonstrated that M-protein light chain (LC) glycosylation can be detected on routine MASS-FIX testing. Glycosylation is increased in patients with immunoglobulin LC amyloidosis (AL) and rarely changes over the course of a patient’s lifetime. To determine the rates of progression to AL and other plasma cell disorders (PCDs), we used residual serum samples from the Olmsted monoclonal gammopathy of undetermined significance (MGUS) screening cohort. Four-hundred and fourteen patients with known MGUS were tested by MASS-FIX, and 25 (6%) were found to have glycosylated LCs. With a median follow-up of surviving patients of 22.2 years, the 20-year progression rates to a malignant PCD were 67% (95% CI 29%, 84%) and 13% (95% CI 9%, 18%) for patients with and without glycosylated LCs, respectively. The risk of progression was independent of Mayo MGUS risk score. The respective rates of progression to AL at 20 years were 21% (95% CI 0.0%, 38%) and 3% (95% CI 0.6%, 5.5%). In summary, monoclonal LC glycosylation is a potent risk factor for progression to AL, myeloma, and other PCDs, an observation which could lead to earlier diagnoses and potentially reduced morbidity and mortality.
AB - Our group previously demonstrated that M-protein light chain (LC) glycosylation can be detected on routine MASS-FIX testing. Glycosylation is increased in patients with immunoglobulin LC amyloidosis (AL) and rarely changes over the course of a patient’s lifetime. To determine the rates of progression to AL and other plasma cell disorders (PCDs), we used residual serum samples from the Olmsted monoclonal gammopathy of undetermined significance (MGUS) screening cohort. Four-hundred and fourteen patients with known MGUS were tested by MASS-FIX, and 25 (6%) were found to have glycosylated LCs. With a median follow-up of surviving patients of 22.2 years, the 20-year progression rates to a malignant PCD were 67% (95% CI 29%, 84%) and 13% (95% CI 9%, 18%) for patients with and without glycosylated LCs, respectively. The risk of progression was independent of Mayo MGUS risk score. The respective rates of progression to AL at 20 years were 21% (95% CI 0.0%, 38%) and 3% (95% CI 0.6%, 5.5%). In summary, monoclonal LC glycosylation is a potent risk factor for progression to AL, myeloma, and other PCDs, an observation which could lead to earlier diagnoses and potentially reduced morbidity and mortality.
UR - http://www.scopus.com/inward/record.url?scp=85086872198&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85086872198&partnerID=8YFLogxK
U2 - 10.1038/s41375-020-0940-8
DO - 10.1038/s41375-020-0940-8
M3 - Article
C2 - 32594098
AN - SCOPUS:85086872198
SN - 0887-6924
VL - 34
SP - 2749
EP - 2753
JO - Leukemia
JF - Leukemia
IS - 10
ER -